At its core, the difference is between measuring what a protein does versus measuring how much of it is there. In complement IVD development, CH50 and AH50 are functional hemolytic assays that evaluate the complete enzymatic cascade activity of the classical and alternative pathways, respectively—they tell you if the system actually works. Antigenic immunoassay kits (ELISAs, turbidimetric, nephelometric) quantify the absolute concentration of specific complement proteins or activation fragments (like C3, C4, C3a, Bb) regardless of whether those molecules are functional or denatured. This fundamental distinction drives everything from raw material selection to clinical interpretation.
Functional hemolytic assays measure the collective lytic ability of entire complement pathways, reflecting true biological activity that depends on all components being active. Antigenic immunoassays measure precise protein mass or activation fragments, providing quantitative molecular data but blind to functional integrity. The right choice—and often the combination of both—is the foundation of accurate complement deficiency diagnosis and kit design.
Two Ways to See the System: Activity vs. Presence
How Functional Hemolytic Assays Work
CH50 and AH50 don’t look at individual proteins; they interrogate the entire pathway by measuring lysis of red blood cells.
CH50 uses antibody-sensitized sheep erythrocytes to trigger the classical pathway, requiring all components from C1 to C9 plus regulatory proteins like C1INH.
AH50 uses rabbit erythrocytes in conditions that block the classical pathway, thus specifically measuring the alternative pathway’s ability to lyse cells via C3, C5–C9, Factors B, D, H, I, and properdin.
These assays quantify the volume of serum needed to lyse 50% of the cells. Any missing, malfunctioning, or consumed component anywhere in the cascade reduces the result.
Because the assay demands intact enzymatic activity and properly preserved serum, it acts as a holistic functional screen.
How Antigenic Immunoassays Work
In contrast, antigenic kits ignore biological activity and focus on physical amount.
They deploy highly specific monoclonal or polyclonal antibodies to bind a target protein (e.g., C3, C4, or a fragment like SC5b-9) and generate a signal proportional to its concentration.
Platforms like ELISA, radial immunodiffusion, turbidimetry, and nephelometry all follow this same principle: measure the mass, not the function.
The results tell you how much protein is present—even if it’s denatured, proteolytically cleaved, or genetically mutated into a non-working form.
This makes them ideal for pinpointing which specific component is consumed, elevated, or absent, but they miss the crucial question: “Does this pool of protein actually function?”
Structural and Raw Material Divergence in Kit Development
Core Reagents for Hemolytic Assays
Building a CH50 or AH50 kit requires biologically active, standardized cellular reagents.
You need calibrated, sensitized sheep or rabbit erythrocytes with consistent stability and a well-defined lysis response to standard serum controls.
The serum controls themselves must be handled to preserve all complement activity—any loss of enzymatic function during storage invalidates the test.
Because these assays measure the cascade output, raw materials are less about individual protein purity and more about overall system integrity and reproducible cell preparations.
Changes in erythrocyte lot or sensitization procedure can shift results, making standardization a primary development challenge.
Core Reagents for Antigenic Assays
Antigenic kits pivot entirely on antibody performance and pure protein standards.
You must source high-affinity, specificity-validated antibodies—often monoclonal pairs for sandwich ELISAs or polyclonal antibodies for turbidimetric reagents—that don’t cross-react with other complement components.
The standard curve relies on purified, stable complement protein calibrators, often produced recombinantly or from highly purified serum fractions, to assign exact concentration units.
Without proper antibody specificity, the assay might measure inactive fragments or aggregated protein, leading to misleadingly high “concentration” readings.
Thus, raw material selection is about molecular recognition rather than biological activity preservation.
Understanding the Trade-offs
Sensitivity to Functional Defects vs. Quantification of Mass
The biggest trade-off is that hemolytic assays are exquisitely sensitive to loss of function but blind to which component failed.
A normal CH50 with low C4 antigen indicates a classic pathway component is consumed but still active enough to lyse cells—information neither test alone could provide.
Conversely, antigenic assays can detect small consumption changes or activation fragment elevations long before functional capacity drops.
They are vital for tracking disease activity in conditions like lupus or C3 glomerulopathy, where complement turnover is key, not just the remaining lytic potential.
Practical Constraints in the Lab
Hemolytic assays require fresh or properly stored serum, consistent erythrocyte preparations, and more hands-on technique.
They are susceptible to pre-analytical variables like warm temperatures or repeated freeze-thaw cycles that destroy enzymatic activity.
Antigenic assays, especially those adapted to automated clinical chemistry analyzers, offer higher throughput and better reproducibility across labs.
However, they can be expensive to set up due to antibody development and purification costs, and they risk giving false reassurance when a protein is present but biologically inert.
How to Apply This to Your IVD Assay Development Strategy
The decision between functional and antigenic methods—or the intelligent pairing of both—depends on the diagnostic question you aim to answer.
- If your primary goal is screening for overall complement deficiency: Start with CH50/AH50 to detect loss of pathway lytic capacity, then use antigenic C3/C4 testing to narrow down the defect.
- If your primary goal is monitoring on‑going complement consumption: Antigenic quantification of C3, C4, and activation fragments like C3a or SC5b-9 delivers the necessary real‑time data; functional assays may remain normal if enough active protein remains.
- If your primary goal is identifying non‑functional protein variants: Only hemolytic assays can unmask mutations that leave antigenic levels normal—combining both tests gives a complete picture of protein presence and capability.
- If your primary goal is sourcing raw materials for kit production: Functional kits demand stable erythrocyte reagents and preserved serum controls; antigenic kits require rigorously characterized antibodies and pure reference standards.
By recognizing that activity and abundance are two distinct lenses on the same system, you can architect a complement testing panel that reveals not just what is present, but what is truly capable of protecting the host.
Summary Table:
| Feature / Parameter | CH50/AH50 Hemolytic Assays | Antigenic Immunoassays (ELISA/Turbidimetry) |
|---|---|---|
| Measurement Focus | Pathway biological activity (lytic capacity) | Absolute protein concentration or mass |
| Target Measured | Entire enzymatic cascade (Classical or Alternative) | Specific protein mass/fragments (e.g., C3, C4, SC5b-9) |
| Core Raw Materials | Sensitized erythrocytes, functionally active serum controls | High-affinity antibodies, purified protein calibrators |
| Sample Sensitivity | High (sensitive to temperature & freeze-thaw cycles) | Moderate to Low (measures mass even if denatured) |
| Primary IVD Utility | Screening complete complement pathway deficiencies | Quantifying specific protein consumption & disease tracking |
Accelerate Your Complement IVD Assay Development with CamelBio
Whether you are developing functional hemolytic assays requiring stable cellular reagents or high-sensitivity antigenic kits needing rigorously characterized antibodies and pure reference standards, CamelBio is your trusted partner.
We provide diagnostic manufacturers, laboratories, and research institutes with one-stop access to premium IVD raw materials, technical services, and specialized consulting—covering every stage of development from initial concept to clinic.
Ready to enhance your assay performance and build reliable, scalable complement diagnostic kits? Contact CamelBio Today to speak with our technical experts.